Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement

David P. Al-Adra; Laura Hammel; John Roberts; E. Steve Woodle; Deborah Levine; Didier Mandelbrot; Elizabeth Verna; Jayme Locke; Jonathan D'Cunha; Maryjane Farr; Deirdre Sawinski; Piyush K. Agarwal; Jennifer Plichta; Sandhya Pruthi; Deborah Farr; Richard Carvajal; John Walker; Fiona Zwald; Thomas Habermann; Morie Gertz; Philip Bierman; Don S. Dizon; Carrie Langstraat; Talal Al-Qaoud; Scott Eggener; John P. Richgels; George J. Chang; Cristina Geltzeiler; Gonzalo Sapisochin; Rocco Ricciardi; Alexander S. Krupnick; Cassie Kennedy; Nisha Mohindra; David P. Foley; Kymberly D. Watt

doi:10.1111/ajt.16318

Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement

David P. Al-Adra, Laura Hammel, John Roberts, E. Steve Woodle, Deborah Levine, Didier Mandelbrot, Elizabeth Verna, Jayme Locke, Jonathan D'Cunha, Maryjane Farr, Deirdre Sawinski, Piyush K. Agarwal, Jennifer Plichta, Sandhya Pruthi, Deborah Farr, Richard Carvajal, John Walker, Fiona Zwald, Thomas Habermann, Morie GertzPhilip Bierman, Don S. Dizon, Carrie Langstraat, Talal Al-Qaoud, Scott Eggener, John P. Richgels, George J. Chang, Cristina Geltzeiler, Gonzalo Sapisochin, Rocco Ricciardi, Alexander S. Krupnick, Cassie Kennedy, Nisha Mohindra, David P. Foley^*, Kymberly D. Watt^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

92 Scopus citations

Abstract

Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.

Original language	English (US)
Pages (from-to)	460-474
Number of pages	15
Journal	American Journal of Transplantation
Volume	21
Issue number	2
DOIs	https://doi.org/10.1111/ajt.16318
State	Published - Feb 2021

Funding

The authors, on behalf of the American Society of Transplantation, thank Sanofi Pharmaceuticals for generously supporting the Malignancy and Transplantation Meeting, held on September 29-30, 2019, in Dallas-Fort Worth. The conference sponsor did not have any role in the study design, collection of literature, interpretation of data, the writing of the report, or the decision to submit the paper for publication. We would also like to thank Dr. Eric Engels for his contribution and critical feedback. In addition, we would like to thank Madeline Hall and the UW Department of Surgery Communications & Marketing division for assistance with the figure creation.

Keywords

cancer / malignancy / neoplasia
clinical research / practice
editorial / personal viewpoint
organ transplantation in general
patient safety
recipient selection

ASJC Scopus subject areas

Immunology and Allergy
Transplantation
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ajt.16318

Cite this

Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D'Cunha, J., Farr, M., Sawinski, D., Agarwal, P. K., Plichta, J., Pruthi, S., Farr, D., Carvajal, R., Walker, J., Zwald, F., Habermann, T., ... Watt, K. D. (2021). Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 21(2), 460-474. https://doi.org/10.1111/ajt.16318

@article{e8779dfd8a484692b35c6b2beb249a13,

title = "Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement",

abstract = "Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.",

keywords = "cancer / malignancy / neoplasia, clinical research / practice, editorial / personal viewpoint, organ transplantation in general, patient safety, recipient selection",

author = "Al-Adra, {David P.} and Laura Hammel and John Roberts and Woodle, {E. Steve} and Deborah Levine and Didier Mandelbrot and Elizabeth Verna and Jayme Locke and Jonathan D'Cunha and Maryjane Farr and Deirdre Sawinski and Agarwal, {Piyush K.} and Jennifer Plichta and Sandhya Pruthi and Deborah Farr and Richard Carvajal and John Walker and Fiona Zwald and Thomas Habermann and Morie Gertz and Philip Bierman and Dizon, {Don S.} and Carrie Langstraat and Talal Al-Qaoud and Scott Eggener and Richgels, {John P.} and Chang, {George J.} and Cristina Geltzeiler and Gonzalo Sapisochin and Rocco Ricciardi and Krupnick, {Alexander S.} and Cassie Kennedy and Nisha Mohindra and Foley, {David P.} and Watt, {Kymberly D.}",

note = "Publisher Copyright: {\textcopyright} 2020 The American Society of Transplantation and the American Society of Transplant Surgeons",

year = "2021",

month = feb,

doi = "10.1111/ajt.16318",

language = "English (US)",

volume = "21",

pages = "460--474",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Elsevier B.V.",

number = "2",

}

Al-Adra, DP, Hammel, L, Roberts, J, Woodle, ES, Levine, D, Mandelbrot, D, Verna, E, Locke, J, D'Cunha, J, Farr, M, Sawinski, D, Agarwal, PK, Plichta, J, Pruthi, S, Farr, D, Carvajal, R, Walker, J, Zwald, F, Habermann, T, Gertz, M, Bierman, P, Dizon, DS, Langstraat, C, Al-Qaoud, T, Eggener, S, Richgels, JP, Chang, GJ, Geltzeiler, C, Sapisochin, G, Ricciardi, R, Krupnick, AS, Kennedy, C, Mohindra, N, Foley, DP & Watt, KD 2021, 'Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement', American Journal of Transplantation, vol. 21, no. 2, pp. 460-474. https://doi.org/10.1111/ajt.16318

TY - JOUR

T1 - Pretransplant solid organ malignancy and organ transplant candidacy

T2 - A consensus expert opinion statement

AU - Al-Adra, David P.

AU - Hammel, Laura

AU - Roberts, John

AU - Woodle, E. Steve

AU - Levine, Deborah

AU - Mandelbrot, Didier

AU - Verna, Elizabeth

AU - Locke, Jayme

AU - D'Cunha, Jonathan

AU - Farr, Maryjane

AU - Sawinski, Deirdre

AU - Agarwal, Piyush K.

AU - Plichta, Jennifer

AU - Pruthi, Sandhya

AU - Farr, Deborah

AU - Carvajal, Richard

AU - Walker, John

AU - Zwald, Fiona

AU - Habermann, Thomas

AU - Gertz, Morie

AU - Bierman, Philip

AU - Dizon, Don S.

AU - Langstraat, Carrie

AU - Al-Qaoud, Talal

AU - Eggener, Scott

AU - Richgels, John P.

AU - Chang, George J.

AU - Geltzeiler, Cristina

AU - Sapisochin, Gonzalo

AU - Ricciardi, Rocco

AU - Krupnick, Alexander S.

AU - Kennedy, Cassie

AU - Mohindra, Nisha

AU - Foley, David P.

AU - Watt, Kymberly D.

PY - 2021/2

Y1 - 2021/2

N2 - Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.

AB - Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.

KW - cancer / malignancy / neoplasia

KW - clinical research / practice

KW - editorial / personal viewpoint

KW - organ transplantation in general

KW - patient safety

KW - recipient selection

UR - http://www.scopus.com/inward/record.url?scp=85093927591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093927591&partnerID=8YFLogxK

U2 - 10.1111/ajt.16318

DO - 10.1111/ajt.16318

M3 - Review article

C2 - 32969590

AN - SCOPUS:85093927591

SN - 1600-6135

VL - 21

SP - 460

EP - 474

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 2

ER -

Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this